235 related articles for article (PubMed ID: 25980761)
1. Hepatitis C treatment and quality of life - You can't always get what you want, but you might get what you need.
Mehta G; Dusheiko G
J Hepatol; 2015 Aug; 63(2):300-2. PubMed ID: 25980761
[No Abstract] [Full Text] [Related]
2. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
[TBL] [Abstract][Full Text] [Related]
3. Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.
Smith SK; Rosenthal P
J Pediatr Gastroenterol Nutr; 2016 Nov; 63(5):516-517. PubMed ID: 27243422
[TBL] [Abstract][Full Text] [Related]
4. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
[TBL] [Abstract][Full Text] [Related]
5. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.
O'Brien TR; Feld JJ; Kottilil S; Pfeiffer RM
Hepatology; 2016 Jan; 63(1):28-30. PubMed ID: 26474163
[No Abstract] [Full Text] [Related]
6. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
7. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Smith MA; Chan J; Mohammad RA
Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.
Chuang WL; Chien RN; Peng CY; Chang TT; Lo GH; Sheen IS; Wang HY; Chen JJ; Yang JC; Knox SJ; Gao B; Garrison KL; Mo H; Pang PS; Hsu YC; Hu TH; Chu CJ; Kao JH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1323-9. PubMed ID: 26841930
[TBL] [Abstract][Full Text] [Related]
9. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K
Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679
[TBL] [Abstract][Full Text] [Related]
10. Seronegative Chronic Hepatitis C Virus Infection: A Teachable Moment.
Craft JF; Ryscavage P
JAMA Intern Med; 2021 Nov; 181(11):1501-1502. PubMed ID: 34515736
[No Abstract] [Full Text] [Related]
11. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
12. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
Ferreira VL; Assis Jarek NA; Tonin FS; Borba HH; Wiens A; Muzzillo DA; Pontarolo R
J Gastroenterol Hepatol; 2017 Apr; 32(4):749-755. PubMed ID: 27785825
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
Curry MP; Tapper EB; Bacon B; Dieterich D; Flamm SL; Guest L; Kowdley KV; Lee Y; Milligan S; Tsai N; Younossi Z; Afdhal NH
Aliment Pharmacol Ther; 2017 Sep; 46(5):540-548. PubMed ID: 28691377
[TBL] [Abstract][Full Text] [Related]
15. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
Barone M; Iannone A; Shahini E; Ippolito AM; Brancaccio G; Morisco F; Milella M; Messina V; Smedile A; Conti F; Gatti P; Santantonio T; Tundo P; Lauletta G; Napoli N; Masetti C; Termite AP; Francavilla R; Di Leo A; Pesce F; Andriulli A
J Viral Hepat; 2018 Jan; 25(1):56-62. PubMed ID: 28787102
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.
Nehra V; Tan EM; Rizza SA; Temesgen Z
Drugs Today (Barc); 2016 Feb; 52(2):111-7. PubMed ID: 27092340
[TBL] [Abstract][Full Text] [Related]
17. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
Abergel A; Metivier S; Samuel D; Jiang D; Kersey K; Pang PS; Svarovskaia E; Knox SJ; Loustaud-Ratti V; Asselah T
Hepatology; 2016 Oct; 64(4):1049-56. PubMed ID: 27351341
[TBL] [Abstract][Full Text] [Related]
18. Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
Schütz A; Moser S; Schwanke C; Schubert R; Luhn J; Gutic E; Lang T; Schleicher M; Haltmayer H; Gschwantler M
J Viral Hepat; 2018 Jul; 25(7):870-873. PubMed ID: 29316001
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
